Cytodyn Inc Stock Price, News & Analysis

CytoDyn Inc. (OTC-PINK: CYDY) responds to an activist group's plan, asserting it lacks compelling strategic direction for cancer therapy approval. The company emphasizes its progress in developing leronlimab, a CCR5 antagonist, achieving faster advancements than prior ownership. Key points include support from top oncologists, a focus on Breakthrough Therapy designation, and a recent Phase 3 trial clearance in Brazil for IV treatment. CytoDyn warns shareholders against the activist group's misleading statements and conflicts of interest, advising no immediate action.

A group of long-time stockholders of CytoDyn Inc. (CYDY) has nominated five director candidates and released a white paper criticizing the company's borrowing practices. Since June 2018, CYDY has relied heavily on borrowing from Iliad Research and Trading, resulting in $142.5 million of convertible notes yielding only $125 million due to high costs. The group calls for accountability from current management, asserting the need for competent leadership to restore investor trust and maximize the company's potential.

CytoDyn Inc. (OTCQB: CYDY) announced a comprehensive business update to be presented by CEO Nader Pourhassan and CMO Scott Kelly at the Emerging Growth Conference on September 29, 2021. The presentation will last 20 minutes, followed by 40 minutes of Q&A.

CytoDyn is developing leronlimab, a CCR5 antagonist with potential uses in treating HIV, cancer, and post-COVID-19 symptoms. The FDA has granted Fast Track designation for two indications related to HIV and metastatic cancer. Phase 2 trials for NASH and long COVID are also underway.

A group of long-time stockholders of CytoDyn Inc. (OTC: CYDY) has announced a strategic plan to secure FDA approval for Leronlimab, a cancer therapy. They have nominated five experienced candidates for the Board, asserting that the current management's approach is ineffective. The plan aims to leverage precision medicine data, combine therapies, prioritize cancer targets, and partner with leading oncology companies. The Group believes this strategy could generate revenue and enhance shareholder value, urging stockholders to vote for their nominees on the WHITE proxy card.

CytoDyn (OTC-PINK: CYDY) has received approval from Brazil’s ANVISA to commence an additional Phase 3 CD16 clinical trial for leronlimab, targeting critically ill COVID-19 patients requiring mechanical ventilation. The trial aims to enroll 316 patients across 22 centers, with an interim analysis planned after 40% enrollment. CytoDyn's CEO highlighted the advantages of IV administration of leronlimab over subcutaneous methods used previously. With a primary endpoint of recovery time, the study builds on previous findings showing significant survival benefits in the critically ill.

CytoDyn, a late-stage biotechnology company, announced that Dr. Scott Kelly will present at the World Antiviral Congress from November 30 to December 2, 2021, in San Diego. His talk, scheduled for November 30 at 2:55 PM PDT, will focus on leronlimab, a CCR5 antagonist with potential applications in treating HIV, COVID-19, and related conditions. Dr. Kelly emphasized the significance of leronlimab’s potential in antiviral therapy, highlighting CytoDyn's ongoing clinical trials and resubmission efforts with the FDA for HIV treatment.

A group of long-time stockholders of CytoDyn Inc. (OTC: CYDY) has announced their commitment to a proxy contest to elect five director candidates to the Board. Judge Maryellen Noreika approved the dismissal of CYDY’s lawsuit aimed at preventing stockholders from voting for these candidates. The stockholders argue that ending the litigation will conserve corporate resources amid dwindling finances due to past management issues. A separate litigation in Delaware remains pending to ensure stockholder voting rights for the nominated candidates.

CytoDyn Inc. announced the resolution of its lawsuit against an activist group led by Paul Rosenbaum and Bruce Patterson, focusing on misleading disclosures regarding conflicts of interest and funding. The activist group reduced its membership from 28 to 7 members and decreased its stake in CytoDyn from 7.67% to 0.96%. New disclosures revealed that the group had not been transparent about its financial backing and conflicts. A hearing regarding the legality of the activist group's director nominations is set for October 6, 2021.

CytoDyn Inc. (OTC: CYDY) announced that its director candidate, Dr. Bruce Patterson, presented at the International COVID Summit in Rome from September 12-14, 2021. The summit gathered noted medical researchers to discuss treatment experiences globally. Dr. Patterson's invitation underscores his leadership in COVID treatment and long-hauler research. The Nominating Stockholders emphasized the importance of Dr. Patterson's expertise as the company seeks FDA approval for Leronlimab, aiming to enhance patient care and create long-term shareholder value.